Singapore markets closed
Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,944.33 +1,559.32 (+2.38%) CMC Crypto 200
1,369.64 -4.20 (-0.31%)
Daiichi Sankyo Company, Limited (DSNKY)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:49PM EDT
| Previous close | 34.98 |
| Open | 35.58 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 35.38 - 35.60 |
| 52-week range | 23.72 - 37.57 |
| Volume | |
| Avg. volume | 196,477 |
| Market cap | 68.112B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 52.20 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.24 (0.70%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- Benzinga
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
- Yahoo Finance
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
- Zacks
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
© 2024 Yahoo. All rights reserved.